A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease. The results of the Phase 3 trial of the drug teriflunomide were published in The New England Journal of Medicine. "This could be a safe, effective and convenient new therapy for multiple sclerosis,"said Dr. Paul O'Connor, the principal investigator for the study and director of the Multiple Sclerosis Clinic at St...
More...
More...